

Supplementary Table 1. HLA Typing of all anti-HMGR subjects

#	Sex	Race	Statin?	A	A	B	B	DRB1	DRB1	DQA	DQA	DQB1	DQB1
1	F	W	No	2		44	60	14	17	1	5	2	5
2	M	W	No	2	3	13	35	7	11	2	5	2	7
3	M	W	Yes	24	32	44	60	4	11	3	5	7	8
4	F	W	Yes	3	29	44	60	4	7	2	3	2	7
5	F	W	Yes	1	2	48	63	4	13	1	3	5	8
6	M	W	Yes	2	31	51	60	4	11	3	5	7	8
7	F	W	Yes	24		35	50	7	11	2	5	2	7
8	M	W	Yes	3	11	35	62	4	11	3	5	7	
9	F	W	Yes	3	68	35	65	11	13	5		7	
10	M	W	Yes	2	11	44	62	4	8	3	4	4	8
11	M	W	Yes	2	23	44	61	11	14	1	5	5	7
12	F	W	Yes	2	29	44		7	11	2	5	2	7
13	M	W	Yes	30		44	51	4	7	2	3	2	8
14	M	W	Yes	1	3	57	62	7	11	2	5	7	9
15	F	W	Yes	2	3	7	51	8	11	5	6	7	
16	F	W	Yes	2		35	72	1	11	1	5	5	7
17	F	W	Yes	2	3	44	60	4	11	3	5	7	
18	M	W	Yes	11	24	18	35	11	16	1	5	5	7
19	M	W	Yes	24	29	44	51	7	11	2	5	2	7
20	F	W	Yes	1		8	27	8	9	3	4	4	9
21	F	B	No	2	36	53	63	11	17	1	5	2	6
22	F	B	No	23	36	8	53	7	11	1	2	2	6
23	F	B	No	3	68	42	71	11	13	1	2	2	5
24	M	B	Yes	24	68	7	72	11	15	1	5	6	7
25	F	B	Yes	30	74	7	72	7	13	1	3	2	6
26	M	B	Yes	2	3	44	58	11	13	3	5	7	9
27	F	B	Yes	23	30	35	49	11	13	1		6	
28	F	B	Yes	74		53	72	11	13	1		5	6

M=male; F=female; W=white; B=black

Supplementary Table 2. Characteristics of statin-intolerant subjects, n = 51*

Gender (M/F)	29/22
Age in years (SD)	56.5 (10.2)
CK in IU/L (SD)	131 (71)
Muscular weakness	
Low (%)	8 (16)
Moderate (%)	9 (18)
Myalgias	
Low (%)	6 (12)
Moderate (%)	19 (37)
Severe (%)	6 (12)
CK > 300 IU/L (%)	3 (6)
Myoglobinuria (%)	6 (12)
Rhabdomyolysis (%)	1 (2)

*As previously published in Mammen, et al., *Arthritis Care Res* (Hoboken). 2011 Oct 3. doi: 10.1002/acr.20662. [Epub ahead of print]